Shares of Amarin (AMRN -4.4%) spike lower after the FDA's latest Orange Book update shows no change in the status of its fish-oil pill Vascepa. M&A speculators had been optimistic on a decision from regulators over the exclusivity of the pill would be coming this month, because last week a draft response letter made the rounds around the FDA which made no mention of 'no decision' this month, as it has previously before.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs